DeepMed Research

THE GEORGE INSTITUTE

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Optimised Treatment for Hypertension Trial

Phase 3

Not yet recruiting

Conditions: Hypertension

First Posted Date: 2025-04-20

Last Posted Date: 2025-04-20

Lead Sponsor: The George Institute

Target Recruit Count: 120

Registration Number: NCT06935760

Locations: 🇦🇺
The George Institute for Global Health, Sydney, New South Wales, Australia

PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury

Phase 3

Not yet recruiting

Conditions: All-cause Mortality
Quality of Life
Neurological Disorder
Acute Brain Injury
Disability, Intellectual
Ventilation, Mechanical
Intensive Care Medicine

Interventions: Drug: Placebo comparator - no ceftriaxone
Drug: Ceftriaxone 2g diluted in >200ml 0.9%sodium chloride

First Posted Date: 2025-02-11

Last Posted Date: 2025-02-11

Lead Sponsor: The George Institute

Target Recruit Count: 3100

Registration Number: NCT06819592

Locations: 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
🇦🇺
Fiona Stanley Hospital, Perth, Western Australia, Australia
🇦🇺
Royal North Shore Hospital, Sydney, New South Wales, Australia

and more 5 locations

The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL

Phase 3

Recruiting

Conditions: Intracerebral Hemorrhage
Spontaneous Intracerebral Hemorrhage
Supratentorial Intracerebral Haemorrhage
Acute Intracerebral Haemorrhage
Acute Stroke

Interventions: Other: Control (Standard treatment)
Drug: Deferoxamine Mesylate
Drug: Colchicine 0.5 mg

First Posted Date: 2025-01-08

Last Posted Date: 2025-04-10

Lead Sponsor: The George Institute

Target Recruit Count: 2000

Registration Number: NCT06763055

Locations: 🇦🇺
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR): a Randomized Controlled Trial

Phase 3

Not yet recruiting

Conditions: Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Aneurysmal
Aneurysmal Subarachnoid Hemorrhage
Hemorrhage, Aneurysmal Subarachnoid

Interventions: Drug: Atorvastatin

First Posted Date: 2024-08-19

Last Posted Date: 2024-08-19

Lead Sponsor: The George Institute

Target Recruit Count: 522

Registration Number: NCT06559072

Locations: 🇨🇳
Tianjin Medical University General Hospital, Tianjin, China

FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage

Phase 2

Not yet recruiting

Conditions: Aneurysmal Subarachnoid Hemorrhage

Interventions: Drug: Placebo
Drug: Fludrocortisone

First Posted Date: 2024-05-10

Last Posted Date: 2024-08-16

Lead Sponsor: The George Institute

Target Recruit Count: 524

Registration Number: NCT06409364

ACT-GLOBAL Adaptive Platform Trial for Stroke

Phase 3

Recruiting

Conditions: Stroke

Interventions: Drug: Standard-dose intravenous tenecteplase
Other: Conservative Blood Pressure Control
Other: Placebo
Other: No deferoxamine mesylate and no colchicine
Drug: Deferoxamine mesylate only
Drug: Low-dose intravenous tenecteplase
Other: Moderate Blood Pressure Control
Drug: NoNO-42
Drug: Colchicine only
Other: No intravenous tenecteplase
Other: Intensive Blood Pressure Control
Drug: Both deferoxamine mesylate and colchicine

First Posted Date: 2024-04-08

Last Posted Date: 2024-11-21

Lead Sponsor: The George Institute

Target Recruit Count: 20000

Registration Number: NCT06352632

Locations: 🇦🇺
The George Institute for Global Health, Sydney, New South Wales, Australia
🇨🇦
University of Calgary, Calgary, Alberta, Canada

Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial

Not Applicable

Recruiting

Conditions: Ischemic Stroke, Acute

Interventions: Other: Intensive SBP Control
Other: Moderate SBP Control
Other: Conservative SBP Control

First Posted Date: 2024-04-08

Last Posted Date: 2024-11-21

Lead Sponsor: The George Institute

Target Recruit Count: 2000

Registration Number: NCT06352619

Locations: 🇦🇺
The George Institute for Global Health, Sydney, New South Wales, Australia
🇨🇦
University of Calgary, Calgary, Alberta, Canada

Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression

Phase 4

Recruiting

Conditions: Treatment Resistant Depression

Interventions: Drug: Racemic ketamine
Drug: Esketamine group

First Posted Date: 2024-02-26

Last Posted Date: 2025-04-08

Lead Sponsor: The George Institute

Target Recruit Count: 162

Registration Number: NCT06278779

Locations: 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺
Black Dog Institute, Randwick, New South Wales, Australia
🇦🇺
Ramsay Clinic Northside, St Leonards, New South Wales, Australia

and more 3 locations

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Phase 3

Recruiting

Conditions: Chronic Kidney Diseases

Interventions: Drug: Placebo Finerenone
Drug: Finerenone

First Posted Date: 2023-09-28

Last Posted Date: 2025-05-01

Lead Sponsor: The George Institute

Target Recruit Count: 1000

Registration Number: NCT06058585

Locations: 🇦🇺
The Canberra Hospital, Garran, Australian Capital Territory, Australia
🇦🇺
Nepean Blue Mountains Local Health District, Kingswood, New South Wales, Australia
🇦🇺
St George Hospital, Kogarah, New South Wales, Australia

and more 22 locations

Preventing the Rise in Blood Pressure With Age Using Reduced-sodium Salt

Not Applicable

Completed

Conditions: Blood Pressure

Interventions: Behavioral: Reduced-sodium potassium-enriched salt

First Posted Date: 2023-06-22

Last Posted Date: 2024-08-29

Lead Sponsor: The George Institute

Target Recruit Count: 148

Registration Number: NCT05912426

Locations: 🇳🇬
Gofidna, Abuja Municipal Area Council, Federal Capital Territory, Nigeria
🇳🇬
Jahi-2, Abuja Municipal Area Council, Federal Capital Territory, Nigeria

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy